Latest Nutraceuticals News

Xenitra Limited has secured a $30 million AUD sales agreement for Danone products with Rockcheck Group and established its Australian subsidiary as an authorised supplier, marking a major step in its China market strategy.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.

Elixinol Wellness Limited (ASX – EXL) has launched a substantial options offer to placement investors and its lead manager, pending shareholder approval. The offer could reshape the company’s capital structure and potentially raise $4.4 million upon exercise.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.